HIV, HCV and Related Comorbidities in Rural Communities Affected by Opioid Injection Drug Epidemics in the United States: Building Systems for Prevention, Treatment and Control (UG3/UH3)

Funding Agency:
National Institutes of Health

This FOA will support biphasic (i.e., two stage, multi-method) research projects that inform community response and promote comprehensive, integrated approaches to prevent HIV and hepatitis C virus (HCV) infection, along with associated comorbidities such as hepatitis B virus (HBV) infection and sexually transmitted diseases (STDs), among people who inject drugs (PWID) in rural US communities. Opioid injection and its consequences (e.g., HIV, HCV, HBV, STDs and overdose) are the primary foci here. These projects should yield evidence of the effectiveness of community response models and best practices in responding to opioid injection epidemics that can be implemented by public health systems in similar rural communities in the US.

The companion announcement to this FOA is RFA-DA-17-023 which will support building capacity for a laboratory to perform next generation sequencing (advanced molecular detection) using Global Hepatitis Outbreak and Surveillance Technology (GHOST), to be developed in collaboration with CDC’s Division of Viral Hepatitis.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): January 10, 2017
  • AIDS Application Due Date(s): January 10, 2017

RFA-DA-17-014 Expiration Date January 11, 2017

Agency Website

Amount Description

Application budgets for UG3 projects must not exceed $400,000 in direct costs for any year of the project.

Application budgets for UH3 projects are not limited but need to reflect the actual needs of the proposed project.

The maximum project period is 5 years: up to 2 years for the first phase (UG3) and up to 3 years for the second phase (UH3).   

Funding Type





Community Outreach and Engagement
Medical - Basic Science
Medical - Clinical Science
Social Sciences

External Deadline

January 10, 2017